So much for the turkey. Staff at US vaccine maker Moderna spent Thanksgiving studying the Omicron coronavirus variant. Moderna’s shares have since risen by a third, as have those of German peer BioNTech. That is a measure of the hopes pinned on mRNA pioneers in the face of the latest threat.
感恩节就这么完了。美国疫苗制造商莫德纳(Moderna)的工作人员在感恩节期间研究了Omicron变种。莫德纳的股价自此上涨了三分之一，德国同行BioNTech也是如此。这表明了人们在面临最新威胁时对mRNA先驱所寄托的希望。
您已阅读12%（406字），剩余88%（2858字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。